Database : MEDLINE
Search on : Patients [Words]
References found : 4507729 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 450773 go to page                         

  1 / 4507729 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 26680247
[Au] Autor:Shaffer KM; Kim Y; Carver CS
[Ad] Address:a Department of Psychology , University of Miami , Coral Gables , FL , USA....
[Ti] Title:Physical and mental health trajectories of cancer patients and caregivers across the year post-diagnosis: a dyadic investigation.
[So] Source:Psychol Health;31(6):655-74, 2016 Jun.
[Is] ISSN:1476-8321
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVE: Evidence suggests interdependence between cancer patients' and their caregivers' physical and mental health. However, the extent to which caregivers' health relates to their patients' recovery, or patients' health affects their caregivers' outcomes, is largely unknown. This dyadic investigation reports the relations between cancer patients' and their caregivers' physical and mental health trajectories during the year following diagnosis. DESIGN: Ninety-two colorectal cancer patient-caregiver dyads completed questionnaires at 2, 6 and 12 months post-diagnosis. OUTCOME MEASURES: Self-reported physical and mental health using the Medical Outcomes Study Short Form Health Survey-12. RESULTS: Patients reported improved physical health over the year following their diagnosis, whereas caregivers reported declining physical health. Patients with lower mental health at diagnosis had stagnated physical health recovery. Caregivers' physical health declined most noticeably among those reporting low mental health at diagnosis and whose patients reported low physical health at diagnosis. CONCLUSION: Findings suggest targeting health interventions to cancer patients and caregivers reporting poor mental health at diagnosis may mitigate their long-term physical morbidity. Limited evidence of dyadic interdependence between patients' and caregivers' physical and mental health trajectories suggests future studies are warranted to identify psychosocial and medical characteristics moderating the relations between patients' and caregivers' health.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Cu] Class update date: 160702
[Lr] Last revision date:160702
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1080/08870446.2015.1131826

  2 / 4507729 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26610259
[Au] Autor:Wong EM; Zhong XB; Sit JW; Chair SY; Leung DY; Leung C; Leung KC
[Ad] Address:a The Nethersole School of Nursing, Chinese University of Hong Kong , Shatin , Hong Kong....
[Ti] Title:Attitude toward the out-patient cardiac rehabilitation program and facilitators for maintenance of exercise behavior.
[So] Source:Psychol Health Med;21(6):724-34, 2016 Sep.
[Is] ISSN:1465-3966
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVE: This study examined the attitudes of Chinese patients with coronary heart disease (CHD) toward the outpatient cardiac rehabilitation program (OCRP), as well as their exercise behavior, intention, maintenance and related factors. METHOD: A qualitative descriptive study design was used, and 22 CHD patients were recruited in Hong Kong in 2014. In-depth interviews and content analyses were conducted. The tripartite model of attitudes was adopted as research framework. RESULT: Two themes were identified: (1) informant attitude (perception, affection, and practice) toward the OCRP and (2) Exercise Behavior - intention, maintenance and its related factors. Most informants showed positive perception and affection regarding the outpatient rehabilitation program, leading to regular practice of exercise in the program and at home. Peer, group dynamic, social support and Chinese culture influences on exercise behavior may serve as major facilitators to maintain exercise behavior. CONCLUSION: Positive attitude toward the OCRP enhanced the participation rate, whereas peer and social support from the family and workplace were useful to improve the maintenance of exercise behavior. Overall, this study provides insights into strategic planning for the OCRP and continual support for CHD patients in the community.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Cu] Class update date: 160702
[Lr] Last revision date:160702
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1080/13548506.2015.1115107

  3 / 4507729 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27335380
[Au] Autor:Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
[Ad] Address:Departments of Pharmaceutical Sciences....
[Ti] Title:Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
[So] Source:Pediatrics;138(1), 2016 Jul.
[Is] ISSN:1098-4275
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:After postoperative deaths in children who were prescribed codeine, several pediatric hospitals have removed it from their formularies. These deaths were attributed to atypical cytochrome P450 2D6 (CYP2D6) pharmacogenetics, which is also implicated in poor analgesic response. Because codeine is often prescribed to patients with sickle cell disease and is now the only Schedule III opioid analgesic in the United States, we implemented a precision medicine approach to safely maintain codeine as an option for pain control. Here we describe the implementation of pharmacogenetics-based codeine prescribing that accounts for CYP2D6 metabolizer status. Clinical decision support was implemented within the electronic health record to guide prescribing of codeine with the goal of preventing its use after tonsillectomy or adenoidectomy and in CYP2D6 ultra-rapid and poor metabolizer (high-risk) genotypes. As of June 2015, CYP2D6 genotype results had been reported for 2468 unique patients. Of the 830 patients with sickle cell disease, 621 (75%) had a CYP2D6 genotype result; 7.1% were ultra-rapid or possible ultra-rapid metabolizers, and 1.4% were poor metabolizers. Interruptive alerts recommended against codeine for patients with high-risk CYP2D6 status. None of the patients with an ultra-rapid or poor metabolizer genotype were prescribed codeine. Using genetics to tailor analgesic prescribing retained an important therapeutic option by limiting codeine use to patients who could safely receive and benefit from it. Our efforts represent an evidence-based, innovative medication safety strategy to prevent adverse drug events, which is a model for the use of pharmacogenetics to optimize drug therapy in specialized pediatric populations.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Cu] Class update date: 160702
[Lr] Last revision date:160702
[Js] Journal subset:AIM; IM
[St] Status:In-Data-Review

  4 / 4507729 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26980915
[Au] Autor:Rosko AJ; Birkeland AC; Wilson KF; Muenz DG; Bellile E; Bradford CR; McHugh JB; Spector ME
[Ad] Address:Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA....
[Ti] Title:Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck.
[So] Source:Otolaryngol Head Neck Surg;155(1):106-12, 2016 Jul.
[Is] ISSN:1097-6817
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To determine biomarkers of recurrence and survival in patients with spindle cell variant squamous cell carcinoma (SpSCC) of the head and neck. STUDY DESIGN: Retrospective case control study. SETTING: Tertiary academic center. SUBJECTS AND METHODS: Thirty-two SpSCC patients (mean age, 68.8) between 1987 and 2009 were identified and reviewed. A tissue microarray (TMA) was constructed from tumor specimens. Tumor biomarkers under study included p16, epidermal growth factor receptor (EGFR), p53, EZH2, cyclin D1, CD104, HGFa, p21, and cMET. An additional TMA was constructed from patients with non-SpSCC oral cavity squamous cell carcinoma for comparative purposes. The main outcomes were overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS). RESULTS: In the SpSCC cohort, tumors positive for cMet had worse OS (P < .001). Patients positive for cMet (P = .007), cyclin D1 (P = .019), and p16 (P = .004) had worse DSS. Recurrence-free survival was also worse in patients with tumors positive for cMet (P = .037), cyclin D1 (P = .012), and p16 (P < .001). Compared with the oral cavity cohort, there was a significantly larger proportion of patients in the SpSCC group with tumors staining positive for cMet and a lower proportion of tumors positive for cyclin D1. CONCLUSION: cMet, cyclin D1, and p16 are predictive tumor biomarkers for risk of recurrence and worse DSS in patients with SpSCC.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Cu] Class update date: 160702
[Lr] Last revision date:160702
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1177/0194599816636612

  5 / 4507729 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27072891
[Au] Autor:Sun M; Asghar SZ; Zhang H
[Ad] Address:Department of Neuroscience and Cell Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, United States.
[Ti] Title:The polarity protein Par3 regulates APP trafficking and processing through the endocytic adaptor protein Numb.
[So] Source:Neurobiol Dis;93:1-11, 2016 Sep.
[Is] ISSN:1095-953X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The processing of amyloid precursor protein (APP) into ß-amyloid peptide (Aß) is a key step in the pathogenesis of Alzheimer's disease (AD), and trafficking dysregulations of APP and its secretases contribute significantly to altered APP processing. Here we show that the cell polarity protein Par3 plays an important role in APP processing and trafficking. We found that the expression of full length Par3 is significantly decreased in AD patients. Overexpression of Par3 promotes non-amyloidogenic APP processing, while depletion of Par3 induces intracellular accumulation of Aß. We further show that Par3 functions by regulating APP trafficking. Loss of Par3 decreases surface expression of APP by targeting APP to the late endosome/lysosome pathway. Finally, we show that the effects of Par3 are mediated through the endocytic adaptor protein Numb, and Par3 functions by interfering with the interaction between Numb and APP. Together, our studies show a novel role for Par3 in regulating APP processing and trafficking.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Cu] Class update date: 160702
[Lr] Last revision date:160702
[Js] Journal subset:IM
[St] Status:In-Data-Review

  6 / 4507729 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26992888
[Au] Autor:Getz SA; DeSpenza T; Li M; Luikart BW
[Ad] Address:Department of Physiology and Neurobiology, Geisel School of Medicine at Dartmouth College Lebanon, NH 03756, United States....
[Ti] Title:Rapamycin prevents, but does not reverse, aberrant migration in Pten knockout neurons.
[So] Source:Neurobiol Dis;93:12-20, 2016 Sep.
[Is] ISSN:1095-953X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:UNLABELLED: Phosphatase and tensin homolog (PTEN) is a major negative regulator of the Akt/mammalian target of rapamycin (MTOR) pathway. Mutations in PTEN have been found in a subset of individuals with autism and macrocephaly. Further, focal cortical dysplasia (FCD) has been observed in patients with PTEN mutations prompting us to examine the role of Pten in neuronal migration. The dentate gyrus of Pten(Flox/Flox) mice was injected with Cre- and non-Cre-expressing retroviral particles, which integrate into the dividing genome to birthdate cells. Control and Pten knockout (KO) cell position in the granule cell layer was quantified over time to reveal that Pten KO neurons exhibit an aberrant migratory phenotype beginning at 7.5days-post retroviral injection (DPI). We then assessed whether rapamycin, a mTor inhibitor, could prevent or reverse aberrant migration of granule cells. The preventative group received daily intraperitoneal (IP) injections of rapamycin from 3 to 14 DPI, before discrepancies in cell position have been established, while the reversal group received rapamycin afterward, from 14 to 24 DPI. We found that rapamycin prevented and reversed somal hypertrophy. However, rapamycin prevented, but did not reverse aberrant migration in Pten KO cells. We also find that altered migration occurs through mTorC1 and not mTorC2 activity. Together, these findings suggest a temporal window by which rapamycin can treat aberrant migration, and may have implications for the use of rapamycin to treat PTEN-mutation associated disorders. SIGNIFICANCE STATEMENT: Mutations in phosphatase and tensin homolog (PTEN) have been linked to a subset of individuals with autism and macrocephaly, as well as Cowden Syndrome and focal cortical dysplasia. Pten loss leads to neuronal hypertrophy, but the role of Pten in neuronal migration is unclear. Here we have shown that loss of Pten leads to aberrant migration, which can be prevented but not reversed by treatment with rapamycin, a mTor inhibitor. These results are important to consider as clinical trials are developed to examine rapamycin as a therapeutic for autism with PTEN mutations. Our findings show that some abnormalities cannot be reversed, and suggest the potential need for genetic screening and preventative treatment.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Cu] Class update date: 160702
[Lr] Last revision date:160702
[Js] Journal subset:IM
[St] Status:In-Data-Review

  7 / 4507729 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26957566
[Au] Autor:Orom H; Biddle C; Underwood W; Nelson CJ; Homish DL
[Ad] Address:Department of Community Health and Health Behavior, University at Buffalo, Buffalo, NY, USA (HO, CB, DLH)Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA (WU)Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA (CJN) horom@...
[Ti] Title:What Is a "Good" Treatment Decision? Decisional Control, Knowledge, Treatment Decision Making, and Quality of Life in Men with Clinically Localized Prostate Cancer.
[So] Source:Med Decis Making;36(6):714-25, 2016 Aug.
[Is] ISSN:1552-681X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: We explored whether active patient involvement in decision making and greater patient knowledge are associated with better treatment decision-making experiences and better quality of life (QOL) among men with clinically localized prostate cancer. Localized prostate cancer treatment decision making is an advantageous model for studying patient treatment decision-making dynamics because there are multiple treatment options and a lack of empirical evidence to recommend one over the other; consequently, it is recommended that patients be fully involved in making the decision. METHODS: Men with newly diagnosed clinically localized prostate cancer (N = 1529) completed measures of decisional control, prostate cancer knowledge, and decision-making experiences (decisional conflict and decision-making satisfaction and difficulty) shortly after they made their treatment decision. Prostate cancer-specific QOL was assessed at 6 months after treatment. RESULTS: More active involvement in decision making and greater knowledge were associated with lower decisional conflict and higher decision-making satisfaction but greater decision-making difficulty. An interaction between decisional control and knowledge revealed that greater knowledge was only associated with greater difficulty for men actively involved in making the decision (67% of sample). Greater knowledge, but not decisional control, predicted better QOL 6 months after treatment. CONCLUSIONS: Although men who are actively involved in decision making and more knowledgeable may make more informed decisions, they could benefit from decisional support (e.g., decision-making aids, emotional support from providers, strategies for reducing emotional distress) to make the process easier. Men who were more knowledgeable about prostate cancer and treatment side effects at the time that they made their treatment decision may have appraised their QOL as higher because they had realistic expectations about side effects.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Cu] Class update date: 160702
[Lr] Last revision date:160702
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1177/0272989X16635633

  8 / 4507729 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27084912
[Au] Autor:Klara K; Collins JE; Gurary E; Elman SA; Stenquist DS; Losina E; Katz JN
[Ad] Address:From the Orthopedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, and the Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital; the Department of Biostatistics, Boston University School of Public Health; and Harvard Medical School; Boston, Ma...
[Ti] Title:Reliability and Accuracy of Cross-sectional Radiographic Assessment of Severe Knee Osteoarthritis: Role of Training and Experience.
[So] Source:J Rheumatol;43(7):1421-6, 2016 Jul.
[Is] ISSN:0315-162X
[Cp] Country of publication:Canada
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To dêtermine the reliability of radiographic assessment of knee osteoarthritis (OA) by nonclinician readers compared to an experienced radiologist. METHODS: The radiologist trained 3 nonclinicians to evaluate radiographic characteristics of knee OA. The radiologist and nonclinicians read preoperative films of 36 patients prior to total knee replacement. Intrareader and interreader reliability were measured using the weighted κ statistic and intraclass correlation coefficient (ICC). Scores κ < 0.20 indicated slight agreement, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 substantial, and 0.81-1.0 almost perfect agreement. RESULTS: Intrareader reliability among nonclinicians (κ) ranged from 0.40 to 1.0 for individual radiographic features and 0.72 to 1.0 for Kellgren-Lawrence (KL) grade. ICC ranged from 0.89 to 0.98 for the Osteoarthritis Research Society International (OARSI) summary score. Interreader agreement among nonclinicians ranged from κ of 0.45 to 0.94 for individual features, and 0.66 to 0.97 for KL grade. ICC ranged from 0.87 to 0.96 for the OARSI Summary Score. Interreader reliability between nonclinicians and the radiologist ranged from κ of 0.56 to 0.85 for KL grade. ICC ranged from 0.79 to 0.88 for the OARSI Summary Score. CONCLUSION: Intrareader and interreader agreement was variable for individual radiograph features but substantial for summary KL grade and OARSI Summary Score. Investigators face tradeoffs between cost and reader experience. These data suggest that in settings where costs are constrained, trained nonclinicians may be suitable readers of radiographic knee OA, particularly if a summary score (KL grade or OARSI Score) is used to determine radiographic severity.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Cu] Class update date: 160702
[Lr] Last revision date:160702
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.3899/jrheum.151300

  9 / 4507729 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27011005
[Au] Autor:Taormina SP; Galloway MP; Rosenberg DR
[Ad] Address:*Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI; †Department of Psychiatry, Children's Hospital of Michigan, Detroit, MI; ‡Department of Anesthesiology, Wayne State University School of Medicine, Detroit, MI.
[Ti] Title:Treatment Efficacy of Combined Sertraline and Guanfacine in Comorbid Obsessive-Compulsive Disorder and Attention Deficit/Hyperactivity Disorder: Two Case Studies.
[So] Source:J Dev Behav Pediatr;37(6):491-5, 2016 Jul-Aug.
[Is] ISSN:1536-7312
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: Treatment of obsessive-compulsive disorder (OCD) is complicated by comorbid psychiatric disorders. Successful treatment of 2 pediatric patients with severe OCD and comorbid attention deficit/hyperactivity disorder (ADHD) is described. METHOD: A report on 2 pediatric clinical cases (Ages 9 and 10) with comorbid OCD and ADHD was used to describe response to medication management through the serotonin transporter inhibitor, sertraline, and the noradrenergic α2A receptor agonist, guanfacine, along with cognitive behavioral therapy. RESULTS: Cognitive behavioral therapy combined with titrated doses of the serotonin transporter inhibitor, sertraline, and the noradrenergic α2A receptor agonist, guanfacine resolved OCD symptoms and the underlying ADHD. CONCLUSION: The novel observations support a focused psychological and pharmacological approach to successful treatment of complex symptoms in patients with comorbid OCD and ADHD. Limitations to generalizability are discussed.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Cu] Class update date: 160702
[Lr] Last revision date:160702
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1097/DBP.0000000000000290

  10 / 4507729 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 27217448
[Au] Autor:Cortes JE; Saglio G; Kantarjian HM; Baccarani M; Mayer J; Boqué C; Shah NP; Chuah C; Casanova L; Bradley-Garelik B; Manos G; Hochhaus A
[Ad] Address:Jorge E. Cortes and Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center, Houston, TX; Neil P. Shah, University of California San Francisco School of Medicine, San Francisco, CA; Brigid Bradley-Garelik and George Manos, Bristol-Myers Squibb, Princeton, NJ; Giuseppe Saglio, Universit...
[Ti] Title:Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
[So] Source:J Clin Oncol;34(20):2333-40, 2016 Jul 10.
[Is] ISSN:1527-7755
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety outcomes of patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with dasatinib or imatinib. PATIENTS AND METHODS: Patients with newly diagnosed CML-CP were randomly assigned to receive dasatinib 100 mg once daily (n = 259) or imatinib 400 mg once daily (n = 260). RESULTS: At the time of study closure, 61% and 63% of dasatinib- and imatinib-treated patients remained on initial therapy, respectively. Cumulative rates of major molecular response and molecular responses with a 4.0- or 4.5-log reduction in BCR-ABL1 transcripts from baseline by 5 years remained statistically significantly higher for dasatinib compared with imatinib. Rates for progression-free and overall survival at 5 years remained high and similar across treatment arms. In patients who achieved BCR-ABL1 ≤ 10% at 3 months (dasatinib, 84%; imatinib, 64%), improvements in progression-free and overall survival and lower rates of transformation to accelerated/blast phase were reported compared with patients with BCR-ABL1 greater than 10% at 3 months. Transformation to accelerated/blast phase occurred in 5% and 7% of patients in the dasatinib and imatinib arms, respectively. Fifteen dasatinib-treated and 19 imatinib-treated patients had BCR-ABL1 mutations identified at discontinuation. There were no new or unexpected adverse events identified in either treatment arm, and pleural effusion was the only drug-related, nonhematologic adverse event reported more frequently with dasatinib (28% v 0.8% with imatinib). First occurrences of pleural effusion were reported with dasatinib, with the highest incidence in year 1. Arterial ischemic events were uncommon in both treatment arms. CONCLUSION: These final results from the DASISION trial continue to support dasatinib 100 mg once daily as a safe and effective first-line therapy for the long-term treatment of CML-CP.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Cu] Class update date: 160702
[Lr] Last revision date:160702
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1200/JCO.2015.64.8899


page 1 of 450773 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information